Jan 8 (Reuters) - Exelixis Inc:
* EXELIXIS - ENTERED INTO EXCLUSIVE COLLABORATION AND LICENSE AGREEMENT WITH STEMSYNERGY THERAPEUTICS
* EXELIXIS INC- AGREEMENT FOR DISCOVERY AND DEVELOPMENT OF NOVEL ONCOLOGY COMPOUNDS TARGETING CASEIN KINASE 1 ALPHA
* EXELIXIS INC- WILL PAY STEMSYNERGY UPFRONT PAYMENT OF $3 MILLION AND UP TO $3.5 MILLION IN INITIAL RESEARCH AND DEVELOPMENT FUNDING
* EXELIXIS INC- CO WILL BE SOLELY RESPONSIBLE FOR COMMERCIALIZATION OF PRODUCTS THAT ARISE FROM COLLABORATION Source text for Eikon: Further company coverage:
 